Dezhan Healthcare (000813.SZ) joint venture company Dongfang Lue cooperates in research and development of new indications and has obtained clinical trial approval.
Deezen Health (000813.SZ) announced that the company recently received a notice from its equity investee, Beijing Dongfanglue Biomedical.
Dezhan Healthcare (000813.SZ) announced that the company recently received a notification from its investee company, Beijing Oriental Strategic Biotechnology Co., Ltd. (referred to as "Oriental Strategic"), regarding the approval of a Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for their joint project with Inovio Pharmaceuticals, Inc. (referred to as "Inovio") on the VGX-3100 project targeting HPV-16/18 related anal precancerous lesions for Phase II clinical trials.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
